AbbVie’s pan-genotypic hepatitis C test drug regimen succeeds in phase 3 trial

Results from a phase 3 clinical trial evaluating AbbVie's investigational pan-genotypic HCV regimen of glecaprevir/pibrentasvir (G/P) demonstrated high SVR rates in chronic hepatitis C patients with s…
Read the full story: PBR - Clinical Trials News